This episode of "The Top Line" is dedicated to Alzheimer’s disease, exploring the latest treatments and what lies ahead.

In the first segment, Fierce Pharma’s Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients. 

Next, Fierce Biotech’s Annalee Armstrong interviews Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They explore the pioneering work being done in Alzheimer's research and discuss the latest breakthroughs. 

In the third segment, Fierce Pharma’s Eric Sagonowsky talks with Reisa Sperling, M.D., who is leading a research team investigating whether Leqembi holds promise in preventing disease progression before any Alzheimer’s symptoms are evident. 

To learn more about the topics in this episode: 

• With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest
• After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
• Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug
• Eisai launches 'digital business' Theoria to build out a dementia ecosystem for patients
• Eisai, Biogen's injectable Leqembi clears toxic protein in Alzheimer's disease. What about safety?
• Experimental Alzheimer's molecule improves cognition in mice by tamping down on inflammation
• Voyager Therapeutics adds anti-amyloid gene therapy to Alzheimer's pipeline
• Acumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active